Search results
Results from the WOW.Com Content Network
Studies of the pathophysiologic mechanisms for the increased risk of Venous thrombosis embolism or VTE after long-distance travel have not produced consistent results, but venous stasis appears to play a major role; other factors specific to air travel may increase coagulation activation, particularly in passengers with individual risk factors ...
"In the AMPLIFY-EXT trial, which added an additional year of treatment, ELIQUIS reduced the composite risk of recurrent venous thromboembolism and total mortality without an increase in major ...
The mainstay of VTE management is anticoagulation therapy, which prevents thrombus propagation and embolization. Such treatment reduces the risk of recurrence. [5] [4] [1] The choice and duration of anticoagulation depend on the individual patient's risk factors, bleeding risk, and preferences.
Numerous medications have been shown to reduce the risk of a person having a VTE, however careful decision making is required in order to decide if a person's risk of having a VTE outweighs the risks associated with most thromboprophylaxis treatment approaches (medications to prevent venous thrombosis).
As such, family history of VTE is a risk factor for a first VTE. [88] Factor V Leiden, which makes factor V resistant to inactivation by activated protein C, [88] mildly increases VTE risk by about three times. [14] [88] Deficiencies of three proteins that normally prevent blood from clotting—protein C, protein S, and antithrombin ...
Dalteparin is a low molecular weight heparin.It is marketed as Fragmin.Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. [2]
For anticoagulant treatment, it is not clear if unfractionated and/or low molecular weight heparin treatment is effective at decreasing mortality and serious adverse events in this population. [19] There is also insufficient evidence to understand the risk of adverse effects associated with these treatment approaches in term or preterm infants.
Obesity dipped slightly in U.S. adults last year for the first time in more than a decade, a study found. The researchers suggested that might be due, in part, to the rise of weight loss drugs ...